Another such agent is ABBV-155 [80], a BCL-XL inhibitor conjugated to a monoclonal antibody against B7H3, which is selectively expressed by cancer cells [81] and by the majority of medulloblastoma tumours [82]. Here, BCL2L1 is linked to neoplasm.